Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nanjing Changao Pharmaceutical, a subsidiary of Shionogi China, is a comprehensive pharmaceutical company based in Nanjing, China, specializing in the research, development, and manufacturing of a wide range of therapeutic products. Founded in 1997 and later integrated into the Shionogi Group, the company operates modern GMP-certified facilities producing various dosage forms, including tablets, capsules, and freeze-dried powder injections. Its product portfolio spans multiple therapeutic areas such as cardiovascular, digestive, and infectious diseases, with notable brands like Aoding (pitavastatin) and Aobo Ping (rabeprazole). In addition to its commercial operations, Nanjing Changao maintains an active R&D pipeline focusing on innovative treatments for conditions like chronic hepatitis B and pulmonary tuberculosis.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nanjing Changao Pharmaceutical.